Remove Clinical Development Remove Government Remove Trials
article thumbnail

9 Ways Worldwide Optimizes Clinical Development for Your Biotech Growth Journey

Conversations in Drug Development Trends

Selecting the right CRO to partner with on your development program is a pivotal decision that can shape the trajectory of your product’s development. Our consultative approach ensures success by integrating research methodology, regulatory affairs strategy, and clinical operations.

article thumbnail

Leveraging Remote-Based Regional Hubs to Improve Efficiencies and Meet Timelines

PPD

Biopharmaceutical and biotech drug developers have faced increasing challenges in recent years. In the past decade alone, the time needed to complete a clinical trial has increased by 20–30%, and the cost to bring a new drug to market has risen to an average of about $2.6

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Managing Opportunities and Risks in Generative AI Use for Clinical Research

PPD

Balancing generative AI opportunities and risks Generative AI offers unparalleled opportunities for transforming various aspects of health care and clinical research. In clinical trials, generative AI accelerates trial designs through protocol optimization and enrollment forecasting, leading to faster and more effective studies.

article thumbnail

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

Two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored by Novavax are fully enrolled, and more than 20,000 participants have been dosed to-date. In alignment with Novavax’ commitment to transparency, Phase 3 clinical trial protocols are posted to the company’s website at Novavax.com/resources upon finalization.

article thumbnail

The Expansion of Cell Therapies in Asia-Pacific

PPD

There has also been an increase in government and regulatory support for CGT trials, in conjunction with an increase in investments for these products to get to market. The government has also enacted strict trade compliance policies that limit genetic materials, such as patient cells, leaving and entering China.

article thumbnail

Bayer and Broad Institute extend cancer therapy research collaboration

Broad Institute

We look forward to continuing our work with renowned Broad scientists to advance additional innovative cancer targets into clinical development.” The research is guided by joint project and governance teams. As a result of this collaboration, Bayer’s mutant EGFR/HER2 inhibitor is currently in Phase I of clinical trials.

Therapies 105
article thumbnail

Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine

The Pharma Data

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1.